ANDA 77013, held by Pharmobedient. Pravastatin Sodium.
As of Nov 16, 2026, ANDA 77013 (Pravastatin Sodium), held by Pharmobedient, was first approved by FDA on Oct 23, 2006, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 23, 2006 | Original application | Approved | None posted |
| Pravastatin Sodium10MG · tablet;oral | Pravastatin Sodium | Discontinued |
| Pravastatin Sodium20MG · tablet;oral | Pravastatin Sodium | Discontinued |
| Pravastatin Sodium40MG · tablet;oral | Pravastatin Sodium | Discontinued |
| Pravastatin Sodium80MG · tablet;oral | Pravastatin Sodium | Discontinued |
| Feb 18, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 18, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 18, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 4, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 28, 2007 | Supplement 2Labeling | Approved | None posted |
| Dec 28, 2007 | Supplement 1Manufacturing | Approved | None posted |
| Oct 23, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters